Regeneron Links With Univ. of Colorado to Sequence 450,000 Patients for Drug Research

Source: FierceBiotech

Regeneron Pharmaceuticals launched a new initiative that plans to sequence the DNA of 450,000 patients and compare the results with their health records, to support the company’s drug discovery and personalized medicine efforts, according to a FierceBiotech report.

With the Colorado Center for Personalized Medicine, part of the University of Colorado Anschutz Medical Campus, the research collaboration will focus on gathering participants across the UCHealth system. The 5-year-old Colorado center already maintains more than 8.7 million de-identified patient records, coupled with a research biobank. Using sequencing data from the Regeneron Genetics Center, it also plans to deliver the test results back to the patients. 

Read the full article.

Related Content